Furthermore, TACE and sorafenib combination (HR, 0.35; 95% CI, 0.16–0.81), Child–Pugh score (HR, 2.21; 95% CI, 1.39–3.51), maximum tumor size (HR, 1.34; 95% CI, 1.18–1.52), BCLC stage A (HR, 0.31; 95% CI, 0.11–0.91), serum AFP > 200 ng/mL (HR, 2.77; 95% CI, 1.29–5.95), and tumor responder (CR + PR) (HR, 0.43; 95% CI, 0.19–0.97) were associated with improved patient survival in the univariate regression analysis (Table 2). This evidence concerns the gene AFP and neoplasm.